<a href="https://laohu8.com/S/IHLXF">Incannex Healthcare</a> Announces Promising Phase 2 Results for IHL-42X, Highlighting Significant Improvements in Sleep and Cognitive Function for OSA Patients
Incannex Healthcare Inc., a clinical-stage pharmaceutical company, has announced new findings from its RePOSA Phase 2 trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The study revealed that 57.6% of participants perceived an improvement in their OSA, with 89.5% of those reporting that the change was meaningful to their lives. Reported benefits included enhanced sleep quality, reduced daytime sleepiness, and fewer cognitive disturbances. These results, collected through structured exit interviews, highlight the potential of IHL-42X to improve both clinical and patient-centric outcomes. The exit interviews were conducted before unblinding and included subjects from placebo, low-dose IHL-42X, and high-dose IHL-42X trial arms. The company has not specified a future date for presenting these findings in a formal publication or conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-073321), on August 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.